Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Omeros
Thumbnail
March 13, 2023

Calliditas sets the bar for its kidney disease rivals

Thumbnail
May 19, 2022

ERA 2022 – Chinook’s second bird could also fly

Article image
Vantage logo
December 16, 2021

Second time lucky for Calliditas

Article image
Vantage logo
November 01, 2021

US FDA approval tracker: October 2021

Article image
Vantage logo
October 22, 2021

Regulatory rejection flurry does not make a storm

Fears of heightened scrutiny by the FDA will be calmed by a look at historic rates of complete response letters.

Article image
Vantage logo
October 01, 2021

Go or no go? UCB bids to make a mark in psoriasis

Chemocentryx and Avadel will also see important FDA regulatory action this month, while Omeros gets another delay.

Article image
Vantage logo
July 21, 2021

Calliditas signs up Stada in Europe

Article image
Vantage logo
June 07, 2021

ERA-EDTA 2021 – Novartis’s iptacopan sets the bar in rare kidney disease

Novartis makes progress with its most valuable pipeline asset, but others also hope to make a mark in IgA nephropathy.

Article image
Vantage logo
November 09, 2020

Armed with data, Calliditas heads to the US

Article image
Vantage logo
May 10, 2019

Upcoming events – binary outcomes for Inflarx and Achieve

Inflarx looks to its lead asset in a rare skin disease, while smoking cessation success could trigger partnering talks for Achieve Life Sciences.

Article image
Vantage logo
November 30, 2018

Upcoming events – Achillion fishes for complements as Aquestive tackles ALS

December will be a big month for Achillion's complement inhibitor and Aquestive's ALS hopes.

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 17, 2023

PD(L)anner – February 2023

February 09, 2023

Biopharma and Medtech Review 2022

View more...

Editor's Picks

Vantage logo
March 13, 2023

Silicon Valley Bank: biopharma’s latest crisis

Vantage logo
March 13, 2023

Pfizer rescues biotech

Vantage logo
February 28, 2023

Why Pfizer (and others) will be interested in Seagen

Vantage logo
March 04, 2023

ACC 2023 – Esperion’s outcomes win looks lacklustre

Vantage logo
March 06, 2023

T-cell receptor behemoths consolidate? Not quite

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up